Nabriva Therapeutics Announces Management Changes

Vienna, Austria- 18 July 2012 - Nabriva Therapeutics, a biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens, has announced various changes to its Management team effective as of the start of July.

Ralf Schmid, formerly Chief Financial Officer (CFO), has taken over from Dr. David Chiswell as Chief Executive Officer (CEO). Dr. Chiswell reverts to his previous role as non-executive chairman of Nabriva’s supervisory board replacing Dr. Denise Pollard-Knight who will remain on the board as Deputy Chair.

In addition to Ralf Schmid (CEO) and William Prince Chief Medical Officer (CMO) there are two new members of management board: Dr. Werner Heilmayer, who has been promoted from Head to Vice President of Chemistry, Manufacturing and Controls & Intellectual Property (VP CMC & IP) and Dr. Zrinka Ivezic-Schönfeld promoted to Vice President Non-Clinical (VP Non-Clinical) from Head of Clinical Sciences.

About Nabriva Therapeutics

Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics for the treatment of serious infections caused by resistant pathogens. Nabriva’s lead systemic product, BC-3781, is being developed for the treatment of serious skin infections and bacterial pneumonia caused by S. aureus, S. pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, L. pneumophila and other bacteria, including drug resistant strains such as MRSA and Vancomycin resistant Enterococcus faecium. Nabriva Therapeutics has a proven track record in world-class medicinal chemistry, clinical expertise, a seasoned management team and solid IP. Nabriva’s current shareholders include: Phase4 Ventures, HBM Partners, Wellcome Trust Investments 3 Unlimited, Global Life Science Ventures, Novartis Venture Fund and Sandoz. Nabriva Therapeutics is located in Vienna, Austria.

For more information on Nabriva please visit

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)